Synthesis and evaluation of 2-amino-6-fluoro-9-(2-hydroxyethoxymethyl)purine esters as potential prodrugs of acyclovir

被引:12
作者
Kim, DK [1 ]
Lee, N [1 ]
Im, GJ [1 ]
Kim, HT [1 ]
Kim, KH [1 ]
机构
[1] SK Chem, Life Sci Res Ctr, Suwon 440745, South Korea
关键词
antivirals; nucleosides; chemotherapy; enzyme inhibitors;
D O I
10.1016/S0968-0896(98)80026-6
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
2-Amino -6-fluoro-9-(2-hydroxyethoxymethyl)purine (2) and its ester derivatives 4a-d were synthesized as potential prodrugs of acyclovir, and were evaluated for their oral acyclovir bioavailability in rats and in vivo antiviral efficacy in HSV-1-infected mice. Treatment of 2-amino-6-chloro-9-(2-hydroxyethoxymethy (3) with trimethylamine in THF/DMF (4:1) followed by a reaction of the resulting trimethylammonium chloride salt 5 with KF in DMF gave 2 in 78% yield. Esterification of 2 with an appropriate acid anhydride (Ac2O, (EtCO)(2)O, (n-PrCO)(2)O, or (i-PrCO)(2)O) in DMF in the presence of a catalytic amount of DMAP at room temperature produced the esters 4a-d in 90-98% yields. Of the prodrugs tested in rats, the isobutyrate 4d achieved the highest mean urinary recovery of acyclovir (51%) that is 5.7-fold higher than that of acyclovir (9%) and comparable to that of valacyclovir (50%). The prodrug 4d protected dose-dependently the mortality of HSV-1-infected mice, and the group treated with 4d at a dose of 400 mg/kg showed the longest mean survival day (14.6 +/- 3.1 days) (mean +/- S.D.). (C) 1998 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:2525 / 2530
页数:6
相关论文
共 13 条
[1]   A RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF ORAL ACYCLOVIR FOR THE PREVENTION OF CYTOMEGALO-VIRUS DISEASE IN RECIPIENTS OF RENAL-ALLOGRAFTS [J].
BALFOUR, HH ;
CHACE, BA ;
STAPLETON, JT ;
SIMMONS, RL ;
FRYD, DS .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (21) :1381-1387
[2]   AMINO-ACID ESTER PRODRUGS OF ACYCLOVIR [J].
BEAUCHAMP, LM ;
ORR, GF ;
DEMIRANDA, P ;
BURNETTE, T ;
KRENITSKY, TA .
ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, 1992, 3 (03) :157-164
[4]   PHARMACOKINETICS OF ACYCLOVIR AFTER INTRAVENOUS AND ORAL-ADMINISTRATION [J].
DEMIRANDA, P ;
BLUM, MR .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1983, 12 :29-37
[5]  
GOOD SS, 1983, J PHARMACOL EXP THER, V227, P644
[6]  
HUFF DG, 1988, J ASS AVIAN VET, V2, P84
[7]   DESIGN AND SYNTHESIS OF 6-FLUOROPURINE ACYCLONUCLEOSIDES - POTENTIAL PRODRUGS OF ACYCLOVIR AND GANCICLOVIR [J].
KIM, DK ;
KIM, HK ;
CHAE, YB .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1994, 4 (11) :1309-1312
[8]   6-DEOXYACYCLOVIR - A XANTHINE OXIDASE-ACTIVATED PRODRUG OF ACYCLOVIR [J].
KRENITSKY, TA ;
HALL, WW ;
DEMIRANDA, P ;
BEAUCHAMP, LM ;
SCHAEFFER, HJ ;
WHITEMAN, PD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1984, 81 (10) :3209-3213
[9]   ACYCLOVIR FOR PREVENTION OF CYTOMEGALO-VIRUS INFECTION AND DISEASE AFTER ALLOGENEIC MARROW TRANSPLANTATION [J].
MEYERS, JD ;
REED, EC ;
SHEPP, DH ;
THORNQUIST, M ;
DANDLIKER, PS ;
VICARY, CA ;
FLOURNOY, N ;
KIRK, LE ;
KERSEY, JH ;
THOMAS, ED ;
BALFOUR, HH .
NEW ENGLAND JOURNAL OF MEDICINE, 1988, 318 (02) :70-75
[10]   ACYCLOVIR - AN UPDATED REVIEW OF ITS ANTIVIRAL ACTIVITY, PHARMACOKINETIC PROPERTIES AND THERAPEUTIC EFFICACY [J].
OBRIEN, JJ ;
CAMPOLIRICHARDS, DM .
DRUGS, 1989, 37 (03) :233-309